Anzeige
Erschienen in:
28.04.2020 | Letter to the Editor
Risk Of Thrombosis In Elderly Immune Primary Trombocytopenic Patients Treated with Thrombopoietin Receptors Agonists
Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2020
Einloggen, um Zugang zu erhaltenExcerpt
-
Low platelet counts in patients with primary immune thrombocytopenia (ITP) are associated with an increased risk for bleeding.
-
Paradoxically, patients with chronic ITP (c ITP) may also have an increased risk for venous thromboembolism (VTE) Few studies have evaluated the VTE risk in elderly c ITP patients compared with general population and in c ITP patients treated in second line therapy with thrombopoietin receptor agonists.
-
TPO‐RAs have significantly changed the management of ITP. Prospective randomized controlled studies demonstrated TPO‐RA efficacy in about 70% of adults with c ITP, with good short‐term safety profile. The two TPO-RA, romiplostim and eltrombopag, represent a completely different approach to ITP; they both have a very good chance of supporting the platelet count. Both drugs bind to the thrombopoietin (TPO) receptor, causing conformational change in the TPO receptor, activation of the JAK2/STAT5 pathway, and a resulting increased megakaryocyte progenitor proliferation and increased platelet production
-
Here we report our single center experience of treatment of ITP population in older patients focusing on thrombotic risk in elderly patients treated with thrombopoietin receptors agonist in c ITP. Data show that C ITP patients have an increased risk of thrombotic events as compared to general population and that c ITP patients exposed to TPO RA have a slight but statistic significant increased risk of VTE
-
Physician should be aware that all available treatments for ITP have significant side‐effects and that their use is justified only if the patient has a real risk of bleeding, not just to correct platelet count toward normality, Treatment should be individualized, taking also into account the values of the patients, especially in elderly patients. Prophylaxis for thrombosis should be done in ITP patients in risky situations like immobilization and surgery (including splenectomy).